Expressing the sense of Congress that governmental entities should use a portion of the proceeds from litigation against opioid manufacturers and distributors to increase participation in drug take back programs and for the safe disposal of collected, unused medicines.

Expressing the sense of Congress that governmental entities should use a portion of the proceeds from litigation against opioid manufacturers and distributors to increase participation in drug take back programs and for the safe disposal of collected, unused medicines.

Summary

Lobbying filings that explicitly cite this bill (2)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Subjects (8)

Actions (3)

Committees

Text Versions

Cosponsors (17)

Similar Bills (AI)

Bills with similar content found using semantic analysis.